Safety and Efficacy Study of BCD-020 in Therapy of Non-Hodgkin's Lymphoma

Brief description of study

This international multi-center, randomized, controlled, open-label study will investigate
the pharmacokinetics, pharmacodynamics, efficacy and safety of BCD-020 (NN: rituximab, CJSC
Biocad) versus MabThera (INN: rituximab, F. Hoffmann La Roche, Ltd.) both administered as a
monotherapy of patients with indolent non-Hodgkin's lymphoma.
Patients will be randomized to receive 375 mg/m² BCD-020 as intravenous infusion once a week
for 4 weeks or MabThera at the same regimen.